Could Biogen Acquire Axsome Therapeutics?
It's been a great year for Biogen (NASDAQ: BIIB). The big biotech won a controversial U.S. approval for its Alzheimer's disease drug Aduhelm. Because of this surprising victory, Biogen's shares have soared close to 40% year to date.
The story hasn't been so great, though, for Axsome Therapeutics (NASDAQ: AXSM). The U.S. Food and Drug Administration (FDA) recently identified issues with the company's filing for approval of AXS-05 in treating major depressive disorder. Axsome stock plunged on the news and is now down more than 70% this year.
But Axsome's pipeline still has plenty of potential. And Biogen seems likely to look for smaller drugmakers to gobble up. Could Biogen acquire Axsome? There are three reasons why the answer could be a resounding "yes."
Source Fool.com
